Search

Displaying results 5041 - 5050 of 10000 in total
  1. Drug

    AZD-9684

    go.drugbank.com/drugs/DB05712
    Experimental

    AZD-9684 is the first member of a new anti-thrombotic class (CPU inhibitors). It is being developed by AstraZeneca.

  2. Drug

    4'-Methylene-5,8,10-trideazaaminopterin

    go.drugbank.com/drugs/DB05616
    Investigational

    CH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier … It has been investigated for the treatment of Rheumatoid Arthritis (phase II).

  3. Drug

    Pivhydrazine

    go.drugbank.com/drugs/DB09252
    ApprovedWithdrawn

    In 1960, it was widely used as an antidepressant agent but it is now discontinued. … Pivhydrazine, also known as pivazide, is a member of the hydrazine family with irreversible and non-selective inhibitory activity against monoamine oxidases.

  4. Drug

    Vintafolide

    go.drugbank.com/drugs/DB05168
    Investigational

    Vintafolide is a folate-targeted chemotherapeutic conjugate (folate vitamin + vinca alkaloid) in clinical stage development as a treatment for folate-receptor positive cancers.

  5. Drug

    Hydroquinidine

    go.drugbank.com/drugs/DB15300
    Investigational

    Hydroquinidine is under investigation in clinical trial NCT00927732 (Hydroquinidine Versus Placebo in Patients With Brugada Syndrome).

    Categories: Antiarrhythmics, Class I, Antiarrhythmics, Class Ia
  6. Drug

    Rolofylline

    go.drugbank.com/drugs/DB12670
    Investigational

    Rolofylline is under clinical development by pharmaceutical company NovaCardia for the treatment of congestive heart failure.

  7. Drug

    Pucotenlimab

    go.drugbank.com/drugs/DB17552
    ApprovedInvestigational

    [A257296] It is being investigated in other cancers. … Pucotenlimab is a recombinant humanized anti-PD-1 monoclonal antibody. It received its first global approval in China in July 2022 for the treatment of solid tumours.

  8. Drug

    GPI-0100

    go.drugbank.com/drugs/DB05929
    Investigational

    GPI-0100 is Avantogen’s lead adjuvanat-immunopotentiator, a key component of vaccines for boosting the immune response. … The GPI-0100 adjuvant, which has been shown to significantly enhance the immune response with a variety of vaccines, has been shown to have good overall performance characteristics on safety and efficacy

  9. Drug

    Fibrinolysin

    go.drugbank.com/drugs/DB05254
    Investigational

    The ointment is marketed by Pfizer under the brand name Fibrolan in a variety of countries (e.g. Switzerland). It is currently not approved in the USA. … Fibrinolysin is used as a local healing ointment when combined together with the enzyme deoxyribonuclease I (extracted from bovine pancreas).

  10. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies. … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.